This activity is for healthcare professionals outside of the UK only.

This activity is provided by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go
    • Downloads
    Download Slides
    Download Practice Aid
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Matthew Lunning

    University of Nebraska Medical Center, Omaha, NE, USA

    Dr Matthew Lunning is an associate professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center (UNMC) in Omaha, USA. He is also associate vice chair of research for the Department of Internal Medicine, assistant vice chancellor of Clinical Research, and medical director of gene and cellular therapies at the UNMC.read more

    Dr Lunning was the recipient of the UNMC Distinguished Scientist Award in 2019. He has served on several National Comprehensive Cancer Network® guidelines committees, including the Management of Immunotherapy-Related Toxicity and T-Cell/Primary Cutaneous Lymphomas panels. He has also served as an invited member of the American Society of Clinical Oncology’s Cancer Education Committee on Non-Hodgkin Lymphoma and is the co-organizer of the Pan Pacific Lymphoma Conference.

    Dr Matthew Lunning discloses: Consultancy fees from AbbVie, Acrotech Biopharma, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, CRISPR Therapeutics, Daiichi Sankyo, Fate Therapeutics, Genentech, Genmab, Incyte Corporation, Ipsen, Janssen Pharmaceuticals, Kite Pharma, Loxo Oncology, Nurix, Recordati, Regeneron Pharmaceuticals, Sanofi, Seagen and Vittoria Biotherapeutics. Grants/Research support from Bristol Myers Squibb, Fate Therapeutics and Sana Therapeutics.
    Prof. Charalambos Andreadis

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

    Prof. Charalambos (Babis) Andreadis is a haematologist specializing in the treatment of lymphoma at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center in San Francisco, USA, where he leads the lymphoma programme. He is also the director of the Baszucki Lymphoma Therapeutic Initiative at UCSF.read more

    He earned his medical degree at Columbia University’s Vagelos College of Physicians and Surgeons, then completed a residency at NewYork-Presbyterian Hospital and a fellowship in haematology and oncology at the Hospital of the University of Pennsylvania.

    Prof. Andreadis’s research focuses on individualized therapies targeting disease subtypes, and immune effector cell therapies for haematological malignancies.

    Prof. Charalambos Andreadis discloses: Advisory board or panel fees from AbbVie, AstraZeneca, Epizyme (an Ipsen company) and Gilead Sciences. Consultancy fees from Atara Biotherapeutics and Bristol Myers Squibb. Grants/Research support from Bristol Myers Squibb, Eli Lilly and Company, Genzyme, Merck, Novartis and Roche.
    Dr Tara Graff

    Mission Cancer and Blood, Des Moines, IA, USA

    Dr Tara Graff is a medical oncologist and has worked at Mission Cancer and Blood in Des Moines, Iowa, USA for 10 years, specializing in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia. She serves as the primary investigator for multiple clinical trials and is the physician director of the clinical trials programme for Mission Cancer and Blood.read more

    Dr Graff serves on the BMS National CAR T-cell Advisory Board for Lymphoma, multiple national lymphoma advisory boards, the NHL Advisory Council and the LBCL (large B-cell lymphoma) Steering Committee. She is a member of the ECOG-ACRIN cancer research group, Lymphoma Working Committee for the Center for International Blood and Marrow Transplant Research and the Lymphoma Research Foundation. She is also the cellular therapy lead and co-chair of the Malignant Hematology Council for Exigent Research.

    Dr Graff has published many original oncology and haematology articles and has paired with the Leukemia & Lymphoma Society to deliver education for patients with cancer in rural areas, and bispecific antibody and CAR T-cell therapy education for community oncologists.

    Dr Tara Graff discloses: Advisory board or panel fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, BeiGene, Eli Lilly and Company, Genmab and Kite Pharma. Consultancy fees from AbbVie, Genentech and Genmab. Speaker’s bureau fees from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Eli Lilly and Company, Genmab and Kite Pharma.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Start activity

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which of these treatments has had the biggest impact on your patients with R/R FL?

    Submit your answer to see the results

    Bispecific antibodies
       
    BTK inhibitors
       
    CAR T-cell therapies
       
    EZH2 inhibitors
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    What do you use most often to guide your treatment sequencing decisions in R/R FL?

    Submit your answer to see the results

    Personal experience and/or guidance from colleague
       
    Clinical or real-world evidence
       
    Patient preference
       
    Other
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    What factor most frequently influences your patients’ treatment decisions in R/R FL?

    Submit your answer to see the results

    Distance to treatment centre
       
    Availability of caregiver support
       
    Treatment administration schedule
       
    Potential impact of the treatment on quality of life/another factor
       
     
    Videos Take CE/CME Test
    Lymphoma, Haematological Malignancies, Haematology CE/CME accredited

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to

    • Analyse the evidence for novel approved therapies in relapsed/refractory follicular lymphoma and their potential impact on the evolving treatment paradigm
    • Practise shared decision-making when individualizing treatment selection for patients with relapsed/refractory follicular lymphoma, with a focus on bispecific antibody and CAR T-cell therapies
    • Evaluate the key considerations for treatment sequencing in relapsed/refractory follicular lymphoma
    Overview

    In this activity, three experts in haematological malignancies provide their perspectives on the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    Community and academic oncologists, haematologists and haemato-oncologists involved in the management of follicular lymphoma

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Dr Matthew Lunning discloses: Consultancy fees from AbbVie, Acrotech Biopharma, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, CRISPR Therapeutics, Daiichi Sankyo, Fate Therapeutics, Genentech, Genmab, Incyte Corporation, Ipsen, Janssen Pharmaceuticals, Kite Pharma, Loxo Oncology, Nurix, Recordati, Regeneron Pharmaceuticals, Sanofi, Seagen and Vittoria Biotherapeutics. Grants/Research support from Bristol Myers Squibb, Fate Therapeutics and Sana Biotechnology.

    Prof. Charalambos Andreadis discloses: Advisory board or panel fees from AbbVie, AstraZeneca, Epizyme (an Ipsen company) and Gilead Sciences. Consultancy fees from Atara Biotherapeutics and Bristol Myers Squibb. Grants/Research support from Bristol Myers Squibb, Eli Lilly and Company, Genzyme, Merck, Novartis and Roche.

    Dr Tara Graff discloses: Advisory board or panel fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, BeiGene, Eli Lilly and Company, Genmab and Kite Pharma. Consultancy fees from AbbVie, Genentech and Genmab. Speaker’s bureau fees from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Eli Lilly and Company, Genmab and Kite Pharma.

    Content reviewer

    Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Director

    Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 08 August 2024. Date credits expire: 08 August 2025.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchPANEL DISCUSSION

    Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial

    GO TO HUB

    CONFERENCE HUB

    Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)

    GO TO HUB

    touchCONGRESS

    Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

    LAUNCH ACTIVITY

    JOURNALS

    Foreword – Oncology & Hematology Review, 2012;8(1):10

    GO TO ARTICLE

    JOURNALS

    Anti-natural Killer Inhibitory Receptors in Elderly Patients with Acute Myeloid Leukaemia

    GO TO ARTICLE

    Topics covered in this activity

    Lymphoma / Haematological Malignancies / Haematology
    This activity is funded by:

    An independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 08 August 2024.  Date credits expire: 08 August 2025.

    Claim Credit
    touchPANEL DISCUSSION
    Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making
    0.75 CE/CME credit
    Question 1/4
    Your 73-year-old patient with follicular lymphoma has experienced disease progression while on their third line of therapy. You are discussing next steps with them when they ask about epcoritamab, and how the response rate compares with therapies routinely used in this setting. Based on an analysis presented at EHA 2024 that compared the efficacy of epcoritamab in the EPCORE NHL-1 trial with usual-care records from the COTA EHR database, what would you tell them? “Compared with usual care, epcoritamab-treated patients…”

    CR, complete response; EHA, European Hematology Association; EHR, electronic health record; ORR, overall response rate.

    A comparison of individual patient data from the EPCORE NHL-1 trial (n=126) and records from the COTA EHR database (n=152) of patients with relapsed/refractory follicular lymphoma receiving treatment in the third- or later-line setting was presented at EHA 2024. Results showed that epcoritamab significantly improved the ORR (86% vs 70%, p=0.002) and CR rate (69% vs 23%, p<0.001) compared with usual care.

    Abbreviations
    CR, complete response; EHA, European Hematology Association; EHR, electronic health record; ORR, overall response rate.

    Reference
    Phillips T, et al. HemaSphere. 2024;8(Suppl.1):2063–4.

    Question 2/4
    You have been discussing initiating CAR T-cell therapy with your 58-year-old patient with relapsed/refractory follicular lymphoma. Which of these factors that you have identified during the shared decision-making process is likely to have the greatest influence on whether they choose this treatment?

    CAR, chimeric antigen receptor.

    Multiple factors influence treatment decisions in follicular lymphoma.1 Utilizing shared decision-making can help identify the patient’s priorities, needs, perceptions and expectations.1,2 Patients receiving CAR T-cell therapy require a caregiver to be available around-the-clock for 4–8 weeks after the infusion.3 The distance from the treatment centre, treatment-related side effects, administration schedule, convenience of administration, speed of access to therapy and the ability of the patient to tolerate therapy are also key factors influencing patient decisions.1,4,5

    Abbreviation
    CAR, chimeric antigen receptor.

    References

    1. Qualls D, Salles G. Haematologica. 2022;107:19–34.
    2. Glatzer M, et al. Oncology. 2020;98:370–8.
    3. Cancer Support Community. CAR T Patient and Caregiver Guide. Available at: www.cancersupportcommunity.org/sites/default/files/fsac/CAR_T_Patient_and_Caregiver_Guide.pdf (accessed 02 July 2024).
    4. Skarbnik AZ, Patel K. Front Oncol. 2023;13:1120358.
    5. Gurumurthi A, et al. Blood Adv. 2023;7:5713–6.
    Question 3/4
    Which of the following factors are contributors to the challenge of determining the optimal treatment sequence in patients with relapsed/refractory follicular lymphoma?

    Treatment sequencing can be challenging in relapsed/refractory follicular lymphoma.1 Key challenges include a wide variation in treatment accessibility,2 lack of published outcome data or limited follow-up availability1,2 and few biological insights or biomarkers to help guide patient selection.1-3 In addition, there is limited knowledge of how treatment affects disease biology and therefore response to the next class of agent.1 Importantly, few patients who have received bispecific antibodies or CAR T-cell therapy have been enrolled in trials for later lines of therapy2 and there are currently no head-to-head trial data available that compare recently approved agents.1–3

    Abbreviation
    CAR, chimeric antigen receptor.

    References

    1. Qualls D, Salles G. Haematologica. 2022;107:19–34.
    2. Linton KM, et al. Hematol Oncol. 2023. DOI: 10.1002/hon.3205 (online ahead of print).
    3. Chen C-JJ, et al. Cancers (Basel). 2023;15:4483.
    Question 4/4
    You have a 63-year-old patient with follicular lymphoma who has relapsed following their second line of therapy. During discussions about their treatment options, they mention that their colleague at work had received an autologous stem cell transplant to treat his follicular lymphoma 5 years ago, and ask if this is a treatment option that they should consider. What would you tell them?

    ASCT, autologous stem cell transplant; R/R FL, relapsed or refractory follicular lymphoma.

    The NCCN guidelines for B-cell lymphomas state that autologous stem cell therapy can be used alongside high-dose therapy (HDT/ASCR) as consolidation therapy in the second line in patients with FL. This is not a preferred regimen and is optional.

    Abbreviations
    HDT/ASCR, high-dose therapy with autologous stem cell rescue; FL, follicular lymphoma; NCCN, National Comprehensive Cancer Network.

    Reference
    NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas Version 2.2024 – 30 April 2024. Available at: www.nccn.org (accessed 08 July 2024).

    Back to Activity

    You may also be interested in...

    touchTALKS

    What’s on the horizon for higher-risk MDS? An update on emerging novel agents

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchCONGRESS

    Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022?

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Shaji Kumar, ASH 2021: Final Overall Survival Results from the BELLINI Study

    GO TO HUB

    JOURNALS

    Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma

    GO TO ARTICLE

    CONFERENCE HUB

    Raajit Rampal, ASH 2019: New Approaches to the Individualized Management of MPNs

    GO TO HUB

    JOURNALS

    Iron Overload, Oxidative Damage and Ineffective Erythropoiesis in Myelodysplastic Syndromes

    GO TO ARTICLE
    This activity is funded by:

    An independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 08 August 2024.  Date credits expire: 08 August 2025.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72